Untitled Document
www.expresspharmaonline.com FORTNIGHTLY INSIGHT FOR PHARMA PROFESSIONALS
1-15 July 2008  
Untitled Document
Sections

Market
Management
Pharma Tech Review
Research
Pharma Life
Healthcare

Services
Open Forum
Appointments
Subscribe/Renew
Archives
Editorial Calendar
Media Kit
Contact Us
Network Sites
Express Computer
CIO Decisions
Express Channel Business
Express Hospitality
Express TravelWorld
feBusiness Traveller
Exp. Healthcare Mgmt.
Express Textile
Group Sites
ExpressIndia
Indian Express
Financial Express




    MARKET - The Business of Pharmaceuticals
 

A Mirage No More
Venturing into the Gulf pharma sector is no easy task, especially since complicated regulations may prove to be a major stumbling block. However, early movers have played their cards well and are poised to reap a bountiful harvest. Manjusha Morgaonkar analyses the sector

Emcure's launches new oncology facility
Emcure Pharmaceuticals has launched a new oncology plant at Hinjwadi, Pune. The facility is spread over an area of 70,000 sq ft. Emcure's total investment for the oncology formulations facility and API facility exceeds $25 million.

'Pharmerging markets will be equal to the top five European markets'
With Indian pharmaceutical market depending heavily on brand extensions rather than new molecules to fuel growth, Shailesh Gadre, Managing Director, ORG IMS, speaks to Viveka Roychowdhury about the promise of pharmerging markets

Growth—the organic way
The challenge is doing things differently and yet getting similar results. This is the mantra that MakroCare, a contract research organisation (CRO) chants. Arshiya Khan analyses the CRO's growth

Arch Pharmalabs acquires majority stake in Benzochem Lifesciences
Arch Pharmalabs has acquired a majority stake in Benzochem Lifesciences for an undisclosed amount. Benzochem is a privately held company, engaged in the manufacture of API and intermediates in the oncology and anti-malarials space.

Sanofi Pasteur to donate H5N1 vaccine to WHO
Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, will donate 60 million doses of H5N1 vaccine to the World Health Organization (WHO) over three years for the establishment of an H5N1 vaccine global stockpile.

Dishman's new plant in Shanghai
Dishman Pharmaceuticals is ready for its first international foray through the organic route.

Suven initiates Phase I clinical trials in Europe
Suven has commenced phase I clinical trials of SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral, CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson’s, schizophrenia.

Gennova Biopharmaceuticals, collaborates with PATH MVI
Gennova Biopharmaceuticals Ltd (GBL) is collaborating with the PATH Malaria Vaccine Initiative (MVI) to create a dedicated malaria vaccine manufacturing facility.

Lupin receives US FDA approval
Lupin's subsidiary in the US, Lupin Pharmaceuticals Inc (LPI) has received tentative approval for the Abbreviated New Drug Application (ANDA) for Escitalopram Oxalate tablets 10 mg and 20 mg from the US Food and Drug Administration (US FDA).

IPCA-Ranbaxy alliance receives US FDA approval
Ipca Laboratories (Ipca) had earlier announced strategic alliance with Ranbaxy Pharamceuticals (Ranbaxy) based in Jacksonville, Florida (USA), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (RLL).

Sandu Pharma's geriatric pain management drug in phase II clinical trials
Mumbai-based Sandu Pharmaceuticals is developing a new drug for geriatric pain management.

Virtual R&D to increase innovation and reduce commercial deficit, by 2020
By 2020, pharma R&D process may be shortened by two-thirds, success rates may dramatically increase, and clinical trial costs could be cut substantially, according to a research report by PriceWaterhouseCoopers, entitled Pharma 2020: Virtual R&D, which path will you take?

Intas Biopharma acquires biologics unit in US
Intas Biopharmaceuticals Limited (IBPL) has acquired US-based biotechnology corporation, Biologics Process Development (BPD), based in Poway, California for an undisclosed amount.

Pre Events

Burrill India life sciences meet
The 3rd Annual Burrill India Life Sciences Meeting held on the 15 June 2008, at the Omni in San Diego, a day prior to Bio 2008 was a resounding success.

CII facilitates business response to HIV/AIDS
Aseminar on 'HIV/AIDS—Business Response to Prevention Care and Treatment—was organised by Confedera-tion of Indian Industry (CII) under the aegis of project—Access to Care and Treatment—in Mumbai.


Untitled Document
Untitled Document
© Copyright 2001: Indian Express Newspapers (Mumbai) Limited (Mumbai, India). All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of the Indian Express Newspapers (Mumbai) Limited. Site managed by BPD.